• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 3. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544

Comprehensive Overview of 3-(4-Aminophenyl)-N,N-dimethylbenzamide (CAS No. 1335041-49-0): Properties, Applications, and Industry Insights

3-(4-Aminophenyl)-N,N-dimethylbenzamide (CAS No. 1335041-49-0) is a specialized organic compound gaining attention in pharmaceutical and material science research. This aromatic amide derivative features a unique molecular structure combining an aminophenyl group with a dimethylbenzamide moiety, making it valuable for diverse applications. The compound's dual functional groups enable versatile reactivity, particularly in drug intermediate synthesis and polymer modification processes.

Recent studies highlight its potential as a building block for kinase inhibitors, aligning with the growing demand for targeted cancer therapies. Researchers are investigating its structure-activity relationships (SAR) to optimize bioavailability and binding affinity—key parameters frequently searched by medicinal chemists. The compound's thermal stability (decomposition point >250°C) also makes it suitable for high-performance material development, addressing industry needs for heat-resistant polymers.

Synthetic routes to 1335041-49-0 typically involve Buchwald-Hartwig amination or Ullmann-type coupling reactions, with yields optimized through palladium catalysis. Analytical characterization via HPLC-MS (purity >98%) and NMR spectroscopy confirms its structural integrity. These technical details respond to frequent search queries about compound validation methods and synthesis optimization strategies in organic chemistry forums.

From an industrial perspective, the compound's scalable synthesis and regulatory compliance (non-hazardous per GHS classification) position it favorably for GMP production. Market analysts note rising demand in Asia-Pacific pharmaceutical hubs, driven by increased R&D investment in small molecule therapeutics. Its patent landscape shows protected applications in neurodegenerative disease treatments—a trending topic in aging population healthcare solutions.

Environmental considerations include its biodegradability profile (OECD 301B >60% in 28 days) and low bioaccumulation potential (logPow 2.1), addressing sustainability concerns in green chemistry initiatives. These attributes make it preferable to traditional halogenated intermediates in alignment with REACH regulations—a frequent search term among EHS professionals.

Future research directions focus on its structure-property relationships for optoelectronic materials development, particularly in organic semiconductors for flexible electronics. This connects with booming interest in wearable technology and IoT devices. The compound's crystallinity modulation through co-crystallization techniques is another active investigation area, responding to pharmaceutical searches about polymorph control strategies.

Quality control protocols emphasize ICH Q3D elemental impurity compliance and residual solvent analysis per USP <467> standards—critical considerations for pharmaceutical excipient applications. These technical specifications answer common queries from quality assurance specialists in FDA-submitted drug applications.

In material science, the π-conjugated system of 3-(4-Aminophenyl)-N,N-dimethylbenzamide enables applications in molecular electronics, particularly as charge transport layers in OLED devices. This aligns with market growth projections for display technologies exceeding $100 billion by 2027. Researchers are exploring its supramolecular interactions for self-healing materials—a hot topic in advanced manufacturing discussions.

Handling recommendations include storage under nitrogen atmosphere at 2-8°C to maintain stability, with compatibility studies showing no degradation in common pharmaceutical solvents (ethanol, PEG 400). These practical details address frequent logistical questions from process chemists and formulation scientists in online technical communities.

• 6274-22-2(4-(Methylcarbamyl)aniline)
• 51207-85-3(4-Amino-N,N-diethylbenzamide)
• 166386-41-0(4-(4-Aminophenyl)-N,N-dimethylbenzamide)
• 6331-71-1(4-Amino-N,N-dimethylbenzamide)
• 79868-19-2(4-amino-N,N-dipropylbenzamide)
• 1334500-06-9((4'-Amino-1,1'-biphenyl-4-yl)(piperidin-1-yl)methanone)
• 68269-83-0(3-Amino-N,N-diethylbenzamide)
• 85592-78-5(Benzamide, 4-amino-N-methyl-N-(phenylmethyl)-)
• 33322-60-0(3-Amino-N,N-dimethylbenzamide)
• 1335041-66-1((4'-Amino-1,1'-biphenyl-3-yl)(pyrrolidin-1-yl)methanone)